GO:0032783 super elongation complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032783 defines the super elongation complex (SEC), a conserved RNA polymerase II elongation factor complex that suppresses transient polymerase pausing and increases the overall rate of transcription elongation.
• The SEC minimally contains an ELL-family transcription factor, an EAF protein, and an AFF-family protein or distant relative, and most likely also P-TEFb and AF9 or ENL.
• P-TEFb is the master regulator of transcription elongation and is a key component or partner of the SEC.
• The SEC is conserved from yeast to humans but is absent from Saccharomyces cerevisiae; in Schizosaccharomyces pombe it contains Ell1, Eaf1, and Ebp1.
• The SEC drives oncogenic transcription in MYCN-amplified neuroblastoma and other malignancies, making it a therapeutic target [1,4].
• Disruption of super-enhancers selectively inhibits tumor oncogenes, a process linked to SEC function.
Description
The super elongation complex (SEC) is a multi-subunit cellular component that functions as a transcription elongation factor complex for RNA polymerase II (Pol II). It increases the overall rate of Pol II transcription elongation by suppressing transient polymerase pausing, a critical regulatory step in gene expression. The SEC is conserved from yeast to humans, although it is absent from Saccharomyces cerevisiae, and in Schizosaccharomyces pombe it contains Ell1, Eaf1, and Ebp1. Researchers study the SEC because it is a central node in transcriptional control, integrating signals that release paused Pol II into productive elongation [3,7]. Dysregulation of SEC components is implicated in cancer, including MYCN-amplified neuroblastoma and leukemias, and in neurodevelopmental disorders such as Rett syndrome through MeCP2 interaction [1,2,4,6]. Understanding the SEC provides mechanistic insight into transcription elongation and offers opportunities for therapeutic intervention in transcriptional addiction [1,4].
super elongation complex At A Glance
| GO ID | GO:0032783 |
|---|---|
| GO term | super elongation complex |
| Ontology | cellular_component |
| Synonym | ELL-EAF complex; ELL-EAF-EBP complex |
| Major function | Increases the overall rate of RNA polymerase II transcription elongation by suppressing transient polymerase pausing |
| Minimal components | ELL-family transcription factor, EAF protein, AFF-family protein or distant relative; most likely also P-TEFb and AF9 or ENL |
| Conservation | Conserved from yeast to humans; present in Schizosaccharomyces pombe (Ell1, Eaf1, Ebp1) but absent from Saccharomyces cerevisiae |
| Related factor | P-TEFb, the master regulator of transcription elongation |
What Is GO:0032783?
According to the Gene Ontology, GO:0032783 (super elongation complex) is a transcription elongation factor complex that increases the overall rate of RNA polymerase II transcription elongation by suppressing transient polymerase pausing. At minimum, the complex contains a transcription factor of the ELL family, an EAF protein, and an AFF family protein or distant relative, and most likely also P-TEFb and AF9 or ENL. The complex is conserved from yeast to humans; in Schizosaccharomyces pombe it contains Ell1, Eaf1, and Ebp1, but it is absent from S. cerevisiae. Synonyms include ELL-EAF complex and ELL-EAF-EBP complex.
Why Is super elongation complex Important in Cell Biology?
The super elongation complex is important because it controls a rate-limiting step in gene expression: the release of paused RNA polymerase II into productive elongation [3,7]. This regulatory point is exploited in development and disease, particularly in cancers that depend on high-level transcription of oncogenes such as MYCN. The SEC also integrates with super-enhancer biology, where disruption of super-enhancers selectively inhibits tumor oncogenes. Moreover, inherited mutations affecting transcription elongation can predispose to blood cancers, highlighting the SEC pathway in leukemogenesis. In neuroscience, MeCP2 interacts with the SEC to regulate transcription, linking the complex to Rett syndrome biology. Thus, the SEC is a focal point for understanding transcriptional control and for developing targeted therapeutics.
• The SEC is a conserved RNA polymerase II elongation factor complex that suppresses transient pausing and increases elongation rate.
• P-TEFb, a master regulator of transcription elongation, is a key component or partner of the SEC.
• The SEC drives transcriptional addiction in MYCN-amplified neuroblastoma, a pediatric cancer with poor prognosis.
• Disruption of super-enhancers selectively inhibits tumor oncogenes, a process functionally linked to SEC activity.
• Inherited blood cancer predisposition can arise through altered transcription elongation involving SEC-related mechanisms.
• MeCP2 interacts with the SEC to regulate transcription, connecting the complex to Rett syndrome and neurodevelopmental disorders.
• The SEC mediates phase transition of SPT5 during transcriptional pause release, linking it to condensate biology.
• Targeting the SEC is a promising strategy for oncogenic transcription-driven tumor malignancies.
• The SEC is absent from Saccharomyces cerevisiae but present in S. pombe, providing a model for evolutionary studies.
• Small molecular inhibitor discovery against the SEC is an active area of cancer research.
What Happens During super elongation complex?
Transcription pause release
In simple terms: The SEC helps RNA polymerase II, which has paused near the start of a gene, to resume and speed up transcription.
The super elongation complex increases the overall rate of RNA polymerase II transcription elongation by suppressing transient polymerase pausing. This pause release is a critical regulatory step, and the SEC is recruited to promoters and enhancers to facilitate it. P-TEFb, the master regulator of transcription elongation, is a key component or partner of the SEC and phosphorylates the C-terminal domain of Pol II and negative elongation factors to promote pause release. The SEC also mediates phase transition of SPT5 during transcriptional pause release, suggesting a role in condensate formation at active genes.
Elongation rate enhancement
In simple terms: Once transcription restarts, the SEC keeps the polymerase moving faster and more processively.
The SEC increases the overall rate of RNA polymerase II transcription elongation. This function is conserved from yeast to humans, with the complex containing ELL-family, EAF, and AFF-family proteins or distant relatives. In Schizosaccharomyces pombe, the complex contains Ell1, Eaf1, and Ebp1, but it is absent from Saccharomyces cerevisiae. The elongation rate enhancement is thought to involve suppression of transient pausing and possibly modulation of elongation factor dynamics [7,8].
Integration with super-enhancer signaling
In simple terms: The SEC is part of the machinery that reads super-enhancers, which are large regulatory regions that drive high expression of key genes.
Disruption of super-enhancers selectively inhibits tumor oncogenes, and this process is functionally linked to SEC activity. The SEC is recruited to super-enhancers and contributes to the high transcriptional output of associated oncogenes such as MYCN in neuroblastoma [4,5]. This integration makes the SEC a central node in transcriptional addiction in cancer [1,4].
Role in developmental and neurological gene regulation
In simple terms: The SEC also helps regulate genes important for brain development and function.
MeCP2 interacts with the super elongation complex to regulate transcription, linking the SEC to Rett syndrome and neurodevelopmental disorders. This interaction suggests that the SEC participates in activity-dependent gene expression in neurons. Additionally, inherited blood cancer predisposition through altered transcription elongation highlights the SEC pathway in hematopoietic development and disease.
Key Genes Involved in GO:0032783 super elongation complex
The following genes and proteins are core components or key interactors of the super elongation complex (GO:0032783), based on the QuickGO definition and published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ELL | ELL-family transcription factor; core component of SEC | Minimal component of SEC; involved in pause release and elongation |
| ELL2 | ELL-family transcription factor; core component of SEC | Paralog of ELL; implicated in SEC function and cancer [1,7] |
| ELL3 | ELL-family transcription factor; core component of SEC | Testis-specific ELL family member; potential role in SEC |
| EAF1 | EAF protein; core component of SEC | Minimal component of SEC; interacts with ELL and AFF |
| EAF2 | EAF protein; core component of SEC | Paralog of EAF1; implicated in SEC and cancer |
| AFF1 | AFF-family protein; core component of SEC | Scaffold for SEC assembly; involved in leukemogenesis |
| AFF4 | AFF-family protein; core component of SEC | Key scaffold of SEC; interacts with P-TEFb and ELL |
| AFF2 | AFF-family protein; distant relative | Fragile X mental retardation gene; potential SEC component |
| AFF3 | AFF-family protein; distant relative | Transcription factor; potential SEC component |
| CDK9 | Cyclin-dependent kinase 9; catalytic subunit of P-TEFb | Master regulator of elongation; phosphorylates Pol II CTD |
| CCNT1 | Cyclin T1; regulatory subunit of P-TEFb | Partners with CDK9; component of SEC |
| CCNT2 | Cyclin T2; regulatory subunit of P-TEFb | Alternative P-TEFb cyclin; component of SEC |
| MLLT3 (AF9) | AF9; component of SEC | Most likely component of SEC; involved in leukemia |
| MLLT1 (ENL) | ENL; component of SEC | Most likely component of SEC; involved in leukemia |
| MECP2 | Methyl-CpG-binding protein 2; interacts with SEC | Regulates transcription; linked to Rett syndrome |
| SUPT5H (SPT5) | SPT5; elongation factor; undergoes phase transition | Mediates pause release with SEC |
| MYCN | Oncogenic transcription factor; target of SEC-driven transcription | Amplified in neuroblastoma; SEC drives its expression |
| BRD4 | Bromodomain-containing protein 4; recruits P-TEFb | Interacts with SEC at super-enhancers |
How Is super elongation complex Regulated?
The super elongation complex is regulated at multiple levels. P-TEFb, the master regulator of transcription elongation, is a key component or partner of the SEC and is itself controlled by reversible phosphorylation and by sequestration in the 7SK snRNP complex. The SEC is recruited to super-enhancers, where BRD4 and other factors facilitate its assembly and activity. Inherited mutations affecting transcription elongation can alter SEC function and predispose to blood cancers. Additionally, MeCP2 interacts with the SEC to regulate transcription, providing a neuron-specific regulatory input. The SEC also mediates phase transition of SPT5 during transcriptional pause release, suggesting regulation by condensate formation.
super elongation complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MYCN | MYCN-amplified neuroblastoma | Neuroblastoma cell lines with MYCN amplification; SEC knockout |
| MECP2 | Rett syndrome | MeCP2 mutant neurons; SEC interaction studies |
| AFF1/AFF4 | Leukemia (MLL fusions) | Leukemia cell lines with MLL-AFF fusions; SEC disruption |
| CDK9 | Multiple cancers; transcriptional addiction | CDK9 inhibitor treatment in cancer cell lines |
| MLLT3 (AF9) | Leukemia | MLL-AF9 leukemia models; SEC component knockout |
Cancer and transcriptional addiction
The super elongation complex drives transcriptional addiction in MYCN-amplified neuroblastoma, where it is required for high-level expression of the MYCN oncogene. Disruption of super-enhancers selectively inhibits tumor oncogenes, a process linked to SEC function. Targeting the SEC for oncogenic transcription-driven tumor malignancies is an active area of small-molecule inhibitor discovery. Inherited blood cancer predisposition through altered transcription elongation further implicates the SEC in leukemogenesis.
Neurodevelopmental disorders
MeCP2 interacts with the super elongation complex to regulate transcription, linking the SEC to Rett syndrome, a severe neurodevelopmental disorder. This interaction suggests that SEC dysfunction may contribute to neurological disease through altered activity-dependent gene expression.
Leukemia and blood cancers
The SEC is involved in leukemogenesis through fusion proteins such as MLL-AF9 and MLL-ENL, which recruit the SEC to target genes. Inherited blood cancer predisposition through altered transcription elongation highlights the SEC pathway in familial leukemia. Small molecular inhibitors targeting the SEC are being explored for leukemia therapy.
From super elongation complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SEC component X regulate MYCN expression? | CRISPR knockout of X in MYCN-amplified neuroblastoma cells |
| Does a point mutation in AFF4 disrupt SEC assembly? | CRISPR point mutation knock-in in cell lines |
| Can we tag endogenous ELL for imaging? | CRISPR knock-in of fluorescent tag at ELL locus |
| Does overexpression of P-TEFb enhance elongation? | CRISPR overexpression of CDK9/CCNT1 in reporter cells |
| Does MeCP2 require SEC for neuronal gene regulation? | MeCP2 mutant neurons with SEC knockdown |
| Can SEC inhibitors selectively kill cancer cells? | Small molecule inhibitor screening in cancer cell lines |
How to Study the super elongation complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Steady-state mRNA levels | Measure transcriptional changes after SEC perturbation |
| PRO-seq | RNA polymerase II pausing and elongation | Assess pause release defects upon SEC loss |
| ChIP-seq | Protein-DNA binding genome-wide | Map SEC component binding at super-enhancers |
| Affinity purification-mass spectrometry | Protein-protein interactions | Identify SEC components and interactors |
| Live-cell imaging | Subcellular localization and dynamics | Visualize SEC recruitment to active genes |
| Phase separation assay | Condensate formation | Test SEC-SPT5 phase transition |
| CRISPR knockout screen | Gene essentiality and synthetic lethality | Find vulnerabilities in SEC-dependent cancers |
| Small molecule inhibitor assay | Cell viability and transcription | Evaluate SEC-targeting drugs |
Transcriptional profiling (RNA-seq, PRO-seq, ChIP-seq)
RNA-seq measures steady-state gene expression changes upon SEC perturbation. PRO-seq and ChIP-seq can assess RNA polymerase II pausing and elongation genome-wide, revealing direct SEC targets [7,8]. These methods are essential to define the transcriptional programs controlled by the SEC.
Proteomics and interactomics
Affinity purification coupled with mass spectrometry identifies SEC components and interactors, such as P-TEFb and AF9/ENL. Proximity labeling can capture dynamic interactions at active genes. These approaches help define the minimal and extended SEC complexes.
Imaging and phase separation assays
Live-cell imaging of fluorescently tagged SEC components can visualize their recruitment to super-enhancers. Phase separation assays can test whether SEC components form condensates with SPT5 during pause release. These methods link SEC function to nuclear organization.
CRISPR screens and functional genomics
Genome-wide CRISPR knockout screens can identify genes that synergize with SEC inhibition. Focused screens can map domains required for SEC assembly and function. These functional genomics approaches accelerate target discovery.
How CRISPR Can Be Used to Study GO:0032783 super elongation complex
Knockout
CRISPR knockout of SEC components such as ELL, AFF4, or CDK9 can abolish complex function and reveal essential roles in transcription elongation. In MYCN-amplified neuroblastoma, knockout of SEC genes reduces MYCN expression and cell viability. Knockout models are also used to study leukemia and neurodevelopmental disorders [2,6].
Point Mutation
CRISPR point mutation knock-in can introduce disease-associated or domain-specific mutations in SEC genes to dissect their functions. For example, mutating phosphorylation sites in CDK9 or interaction domains in AFF4 can test their role in pause release [3,7]. These models provide fine-grained mechanistic insight.
Knock-in
CRISPR knock-in of epitope tags, fluorescent proteins, or degron tags at endogenous SEC loci enables real-time tracking and rapid depletion of complex components. Tagged knock-in models are valuable for imaging SEC dynamics at super-enhancers. They also facilitate proteomic studies of endogenous complexes.
Overexpression
CRISPR overexpression of SEC components such as P-TEFb subunits can enhance elongation and drive oncogenic transcription. Overexpression models are used to study transcriptional addiction and to test whether increased SEC activity is sufficient for transformation [1,4]. These models complement loss-of-function studies.
How EDITGENE Supports super elongation complex Research
Researchers studying super elongation complex-related genes often need to determine whether a candidate gene is causally involved in transcription elongation, oncogenic transcription, or neurodevelopmental disease. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for super elongation complex research.
Frequently Asked Questions About super elongation complex
What is the super elongation complex (GO:0032783)?
The super elongation complex (SEC) is a transcription elongation factor complex that increases the overall rate of RNA polymerase II transcription elongation by suppressing transient polymerase pausing.
What genes are involved in the super elongation complex?
Core genes include ELL family members (ELL, ELL2, ELL3), EAF proteins (EAF1, EAF2), AFF family proteins (AFF1, AFF4, AFF2, AFF3), and most likely P-TEFb (CDK9, CCNT1/2) and AF9 or ENL.
Where is the super elongation complex located in the cell?
The SEC is a nuclear complex that associates with chromatin at promoters and enhancers, including super-enhancers [5,7].
What is the function of the super elongation complex?
It suppresses transient RNA polymerase II pausing and increases the rate of transcription elongation, thereby controlling gene expression.
Is the super elongation complex conserved in yeast?
Yes, it is conserved from yeast to humans, but it is absent from Saccharomyces cerevisiae; in Schizosaccharomyces pombe it contains Ell1, Eaf1, and Ebp1.
How is the super elongation complex regulated?
It is regulated by P-TEFb, which is the master regulator of transcription elongation, and by recruitment to super-enhancers; MeCP2 also interacts with the SEC to regulate transcription [2,3,5].
What diseases are associated with the super elongation complex?
The SEC is implicated in cancers such as MYCN-amplified neuroblastoma and leukemias, and in neurodevelopmental disorders like Rett syndrome [1,2,4,6].
What research methods are used to study the super elongation complex?
Common methods include RNA-seq, PRO-seq, ChIP-seq, proteomics, live-cell imaging, phase separation assays, and CRISPR screens [1,4,5,7,8].
Can CRISPR be used to study the super elongation complex?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect SEC function and its role in disease [1,4,7].
Why is the super elongation complex a cancer drug target?
Because it drives oncogenic transcription in cancers with transcriptional addiction, and small molecule inhibitors targeting the SEC are being developed [1,4].
Conclusion
The super elongation complex (GO:0032783) is a conserved, multi-subunit RNA polymerase II elongation factor complex that controls a rate-limiting step in gene expression by suppressing transient pausing. Its core components, including ELL, EAF, AFF, and P-TEFb, are central to transcriptional regulation and are implicated in cancer, leukemia, and neurodevelopmental disorders [1,2,3,4,6]. Continued research using CRISPR-based models and functional genomics will further illuminate SEC biology and its therapeutic potential [1,7].
References
- 1. Wu X et al.. 2023. Targeting the super elongation complex for oncogenic transcription driven tumor malignancies: Progress in structure, mechanisms and small molecular inhibitor discovery.. Adv Cancer Res 158:387-421 PMID: 36990537
- 2. Sonn JY et al.. 2025. MeCP2 interacts with the super elongation complex to regulate transcription.. Sci Adv 11(48):eadt5937 PMID: 41296873
- 3. Fujinaga K et al.. 2023. P-TEFb: The master regulator of transcription elongation.. Mol Cell 83(3):393-403 PMID: 36599353
- 4. Wang D et al.. 2023. The super elongation complex drives transcriptional addiction in MYCN-amplified neuroblastoma.. Sci Adv 9(13):eadf0005 PMID: 36989355
- 5. Lovén J et al.. 2013. Selective inhibition of tumor oncogenes by disruption of super-enhancers.. Cell 153(2):320-34 PMID: 23582323
- 6. Zhao J et al.. 2024. Inherited blood cancer predisposition through altered transcription elongation.. Cell 187(3):642-658.e19 PMID: 38218188
- 7. Luo Z et al.. 2012. The super elongation complex (SEC) family in transcriptional control.. Nat Rev Mol Cell Biol 13(9):543-7 PMID: 22895430
- 8. Guo C et al.. 2023. The super elongation complex (SEC) mediates phase transition of SPT5 during transcriptional pause release.. EMBO Rep 24(3):e55699 PMID: 36629390
